NCT06928883View on ClinicalTrials.gov

Ticin Pilot Study: Sirolimus-Eluting Balloon for Stabilization and Regression of Non-Obstructive Coronary Plaques.

NANot yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2028

Conditions
Coronary Arterial Disease (CAD)Vulnerable Coronary PlaquesMultivessel Coronary Artery DiseaseCoronary VesselAcute Coronary Syndromes (ACS)
Interventions
DEVICE

Sirolimus drug eluting ballooon therapy

Non-flow limiting vulnerable coronary plaques are treated using sirolimus drug eluting balloon therapy additional to guidelines directed medical therapy.

DRUG

Optimal guidelines-directed medical therapies (GDMT)

Optimal guidelines-directed medical therapies (GDMT) to reduce plaque burden and vulnerability for non-flow limiting vulnerable plaques

Trial Locations (1)

6900

Istituto Cardiocentro Ticino - EOC, Lugano

All Listed Sponsors
lead

Cardiocentro Ticino

OTHER

NCT06928883 - Ticin Pilot Study: Sirolimus-Eluting Balloon for Stabilization and Regression of Non-Obstructive Coronary Plaques. | Biotech Hunter | Biotech Hunter